A myriad of AI, science, and technology experts explore the real challenges and enormous opportunities facing entrepreneurs who are building the future of health. Raising Health, a podcast by a16z Bio + Health and hosted by Kris Tatiossian and Olivia Webb, dives deep into the heart of biotechnology and healthcare innovation. Join veteran company builders, operators, and investors Vijay Pande, Julie Yoo, Vineeta Agarwala, and Jorge Conde, along with distinguished guests like Mark Cuban, Greg ...
…
continue reading
InnehÄll tillhandahÄllet av Jon Chee. Allt poddinnehÄll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahÄlls direkt av Jon Chee eller deras podcastplattformspartner. Om du tror att nÄgon anvÀnder ditt upphovsrÀttsskyddade verk utan din tillÄtelse kan du följa processen som beskrivs hÀr https://sv.player.fm/legal.
Player FM - Podcast-app
GĂ„ offline med appen Player FM !
GĂ„ offline med appen Player FM !
𧏠Martin Brenner - iBio - Part 3 | Transitioning from Big Pharma to Biotech Startups | Lessons in Flexibility, Resilience, & Adaptability | Challenging Long-Held Beliefs in Drug Discovery | The Evolution & Future of iBio
MP3•Episod hem
Manage episode 404960591 series 3461709
InnehÄll tillhandahÄllet av Jon Chee. Allt poddinnehÄll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahÄlls direkt av Jon Chee eller deras podcastplattformspartner. Om du tror att nÄgon anvÀnder ditt upphovsrÀttsskyddade verk utan din tillÄtelse kan du följa processen som beskrivs hÀr https://sv.player.fm/legal.
Part 3 of 3.
My guest for this weekâs episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.
My guest for this weekâs episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.
Martin is a seasoned executive and drug hunter with a unique journey spanning electrical engineering to veterinary medicine to scientific leadership roles. He has led drug discovery teams at several top global pharma companies, including Eli Lilly, Pfizer, AstraZeneca, and Merck. Prior to his current role at iBio, Martin was VP and head of R&D at Stoke Therapeutics, CSO at Recursion, and CSO at Phoenix, which was eventually acquired by Ligon Pharmaceuticals.
In part 3 of our conversation with Martin, we chat about his journey from working at large pharmaceutical companies to joining biotech startups. He discusses the importance of mental flexibility, adaptability, and resilience in the biotech industry and reflects on his experiences at Stoke Therapeutics, Recursion, and Pfenex Inc., highlighting the challenges and triumphs of building innovative biotech solutions. He also talks about the significance and importance of strong team dynamics, runway management, and the need to challenge long-held beliefs in the ever-evolving biotech landscape. Please enjoy my conversation with Martin Brenner.
Find Our Guest, Martin Brenner, at these links:
Find Our Guest, Martin Brenner, at these links:
Find Our Host, Jon Chee, at these links:
Timestamps:
00:00:29 Intro
00:01:13 Transitioning from Big Pharma to the startup world; startup needs
00:02:43 Joining the team at Stoke Therapeutics
00:03:35 Resilience & adaptability playing a key role in startups
00:04:34 Martinâs time working with Art Levin
00:07:10 Asking for help & leveraging AppleTreeâs family of companies
00:10:45 Transitioning from Stoke Therapeutics to Recursion
00:12:17 The challenges at Recursion & starting fresh
00:13:33 Building a line-of-sight program
00:15:52 The challenge of questioning established processes
00:16:48 The idea & pitch behind Enveda Biosciences
00:18:55 The differences & similarities between entrepreneurs
00:20:16 Reflecting on processes & continuously learning
00:24:04 Martinsâ move from Recursion to Pfenex Inc. & building the team
00:28:40 The importance of understanding personnel
00:30:17 Martinâs team at Pfenex & the Merger with Ligand
00:31:54 Going through the ups & downs of the M&A process
00:33:47 Post-acquisition integration & cultural resonance
00:35:05 Martinâs opportunity at iBio
00:37:17 The challenges at iBio & their strategy shift
00:41:17 iBioâs current technology & development of antibodies
00:51:46 iBioâs new direction & search for strategic partnerships
00:59:57 Martinâs experience running a publicly traded company
01:03:35 The importance of development & succession plans
01:05:56 Martinâs experience as CEO & learning how to speak finance
01:09:46 Hitting major milestones on iBioâs horizon
01:14:24 Martin thanks those who have supported him
01:17:02 The things Martin would tell his younger self: get into biotech sooner
01:19:02 Outro
Social & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Enriched Notes:
Enriched Notes:
Topics Mentioned:
SCN1A on Dravet syndrome: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739186/
In Vitro screening: https://www.sciencedirect.com/topics/chemistry/in-vitro-screening
Understanding IND applications: https://www.excedr.com/blog/ind-application-process
Biotech Funding Options: https://www.excedr.com/resources/biotech-startup-funding-options
Understanding Debt & Equity Options for Your Funding: https://www.excedr.com/resources/debt-equity-options-funding-startup
Guide to CMOs & CDMOs: https://www.excedr.com/blog/contract-manufacturing-organizations
Guide to Cash Runway: https://www.excedr.com/blog/what-is-cash-runway
Monoclonal Antibodies: https://www.excedr.com/blog/monoclonal-antibody-research-and-production
Primary Antibody Overview: https://www.excedr.com/resources/primary-antibody
Secondary Antibody Overview: https://www.excedr.com/resources/secondary-antibody
Antibody Drug Conjugates: https://www.nature.com/articles/s41392-022-00947-7
Phage Display Overview: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656071/
Licensing in Biotech: https://www.excedr.com/blog/life-sciences-licensing-agreements-guide
People Mentioned:
Isabel Aznares: https://www.linkedin.com/in/isabel-aznarez-aaa21417/
Paul DaSilva-Jardine: https://www.linkedin.com/in/paul-dasilva-jardine-9a791b65/
Viswa Colluru: https://www.linkedin.com/in/viswacolluru/
Eef Schimmelpennink: https://www.linkedin.com/in/eef-schimmelpennink-03b4a45/
Shawn Scranton: https://www.linkedin.com/in/shawn-scranton-pharmd-15046ab3/
Diane Retallack: https://www.linkedin.com/in/diane-retallack-b311392/
Jeff Allen: https://www.linkedin.com/in/jeff-allen-8128585/
Matt Foehr: https://www.linkedin.com/in/matt-foehr-3a47312/
Lisa Middlebrook: https://www.linkedin.com/in/lisamiddleb/
Matt Greving: https://www.linkedin.com/in/matthewgreving/
Saswata Talukdar: https://www.linkedin.com/in/saswata-talukdar-3b20942a/
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
89 episoder
MP3•Episod hem
Manage episode 404960591 series 3461709
InnehÄll tillhandahÄllet av Jon Chee. Allt poddinnehÄll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahÄlls direkt av Jon Chee eller deras podcastplattformspartner. Om du tror att nÄgon anvÀnder ditt upphovsrÀttsskyddade verk utan din tillÄtelse kan du följa processen som beskrivs hÀr https://sv.player.fm/legal.
Part 3 of 3.
My guest for this weekâs episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.
My guest for this weekâs episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.
Martin is a seasoned executive and drug hunter with a unique journey spanning electrical engineering to veterinary medicine to scientific leadership roles. He has led drug discovery teams at several top global pharma companies, including Eli Lilly, Pfizer, AstraZeneca, and Merck. Prior to his current role at iBio, Martin was VP and head of R&D at Stoke Therapeutics, CSO at Recursion, and CSO at Phoenix, which was eventually acquired by Ligon Pharmaceuticals.
In part 3 of our conversation with Martin, we chat about his journey from working at large pharmaceutical companies to joining biotech startups. He discusses the importance of mental flexibility, adaptability, and resilience in the biotech industry and reflects on his experiences at Stoke Therapeutics, Recursion, and Pfenex Inc., highlighting the challenges and triumphs of building innovative biotech solutions. He also talks about the significance and importance of strong team dynamics, runway management, and the need to challenge long-held beliefs in the ever-evolving biotech landscape. Please enjoy my conversation with Martin Brenner.
Find Our Guest, Martin Brenner, at these links:
Find Our Guest, Martin Brenner, at these links:
Find Our Host, Jon Chee, at these links:
Timestamps:
00:00:29 Intro
00:01:13 Transitioning from Big Pharma to the startup world; startup needs
00:02:43 Joining the team at Stoke Therapeutics
00:03:35 Resilience & adaptability playing a key role in startups
00:04:34 Martinâs time working with Art Levin
00:07:10 Asking for help & leveraging AppleTreeâs family of companies
00:10:45 Transitioning from Stoke Therapeutics to Recursion
00:12:17 The challenges at Recursion & starting fresh
00:13:33 Building a line-of-sight program
00:15:52 The challenge of questioning established processes
00:16:48 The idea & pitch behind Enveda Biosciences
00:18:55 The differences & similarities between entrepreneurs
00:20:16 Reflecting on processes & continuously learning
00:24:04 Martinsâ move from Recursion to Pfenex Inc. & building the team
00:28:40 The importance of understanding personnel
00:30:17 Martinâs team at Pfenex & the Merger with Ligand
00:31:54 Going through the ups & downs of the M&A process
00:33:47 Post-acquisition integration & cultural resonance
00:35:05 Martinâs opportunity at iBio
00:37:17 The challenges at iBio & their strategy shift
00:41:17 iBioâs current technology & development of antibodies
00:51:46 iBioâs new direction & search for strategic partnerships
00:59:57 Martinâs experience running a publicly traded company
01:03:35 The importance of development & succession plans
01:05:56 Martinâs experience as CEO & learning how to speak finance
01:09:46 Hitting major milestones on iBioâs horizon
01:14:24 Martin thanks those who have supported him
01:17:02 The things Martin would tell his younger self: get into biotech sooner
01:19:02 Outro
Social & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Enriched Notes:
Enriched Notes:
Topics Mentioned:
SCN1A on Dravet syndrome: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739186/
In Vitro screening: https://www.sciencedirect.com/topics/chemistry/in-vitro-screening
Understanding IND applications: https://www.excedr.com/blog/ind-application-process
Biotech Funding Options: https://www.excedr.com/resources/biotech-startup-funding-options
Understanding Debt & Equity Options for Your Funding: https://www.excedr.com/resources/debt-equity-options-funding-startup
Guide to CMOs & CDMOs: https://www.excedr.com/blog/contract-manufacturing-organizations
Guide to Cash Runway: https://www.excedr.com/blog/what-is-cash-runway
Monoclonal Antibodies: https://www.excedr.com/blog/monoclonal-antibody-research-and-production
Primary Antibody Overview: https://www.excedr.com/resources/primary-antibody
Secondary Antibody Overview: https://www.excedr.com/resources/secondary-antibody
Antibody Drug Conjugates: https://www.nature.com/articles/s41392-022-00947-7
Phage Display Overview: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656071/
Licensing in Biotech: https://www.excedr.com/blog/life-sciences-licensing-agreements-guide
People Mentioned:
Isabel Aznares: https://www.linkedin.com/in/isabel-aznarez-aaa21417/
Paul DaSilva-Jardine: https://www.linkedin.com/in/paul-dasilva-jardine-9a791b65/
Viswa Colluru: https://www.linkedin.com/in/viswacolluru/
Eef Schimmelpennink: https://www.linkedin.com/in/eef-schimmelpennink-03b4a45/
Shawn Scranton: https://www.linkedin.com/in/shawn-scranton-pharmd-15046ab3/
Diane Retallack: https://www.linkedin.com/in/diane-retallack-b311392/
Jeff Allen: https://www.linkedin.com/in/jeff-allen-8128585/
Matt Foehr: https://www.linkedin.com/in/matt-foehr-3a47312/
Lisa Middlebrook: https://www.linkedin.com/in/lisamiddleb/
Matt Greving: https://www.linkedin.com/in/matthewgreving/
Saswata Talukdar: https://www.linkedin.com/in/saswata-talukdar-3b20942a/
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
89 episoder
Alla avsnitt
×VĂ€lkommen till Player FM
Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den Àr den bÀsta podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.